Therapeutic Approaches and Vaccination in Fighting COVID-19 Infections: A Review

Overview

Journal Gene Rep

Date 2022 May 9

PMID 35530725

Authors

Setare Adibzadeh

Shahin Amiri

Giti Esmail Nia

Maryam Rezakhani Taleghani

Zahra Kohanrooz Bijarpas

Neda Maserat

Amirhosein Maali

Mehdi Azad

Abbas Behzad-Behbahani

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals.

Citing Articles

A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.

Maali A, Noei A, Feghhi-Najafabadi S, Sharifzadeh Z Iran Biomed J. 2025; 28(5 & 6):221-34.

PMID: 39891450 PMC: 11829154. DOI: 10.61186/ibj.4444.

Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.

Sadat Larijani M, Biglari A, Sorouri R, Salehi-Vaziri M, Doroud D, Azadmanesh K Iran Biomed J. 2024; 28(1):1-7.

PMID: 38224028 PMC: 10994636. DOI: 10.61186/ibj.3964.

One-step-one-pot hydrothermally derived metal-organic-framework-nanohybrids for integrated point-of-care diagnostics of SARS-CoV-2 viral antigen/pseudovirus utilizing electrochemical biosensor chip.

Palanisamy S, Lee L, Kao C, Chen W, Wang H, Shen S Sens Actuators B Chem. 2023; 390:133960.

PMID: 37193120 PMC: 10170875. DOI: 10.1016/j.snb.2023.133960.

References

Luo P, Qiu L, Liu Y, Liu X, Zheng J, Xue H . Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg. 2020; 103(1):69-72. PMC: 7356425. DOI: 10.4269/ajtmh.20-0375. View

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

Zu Z, Di Jiang M, Xu P, Chen W, Ni Q, Lu G . Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020; 296(2):E15-E25. PMC: 7233368. DOI: 10.1148/radiol.2020200490. View

McGowan E, Haddadi N, Nassif N, Lin Y . Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. Int J Mol Sci. 2020; 21(19). PMC: 7583882. DOI: 10.3390/ijms21197189. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

Kandeel M, Yamamoto M, Al-Taher A, Watanabe A, Oh-Hashi K, Park B . Small Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Fusion by Targeting Cavities on Heptad Repeat Trimers. Biomol Ther (Seoul). 2020; 28(4):311-319. PMC: 7327142. DOI: 10.4062/biomolther.2019.202. View

Beddingfield B, Iwanaga N, Chapagain P, Zheng W, Roy C, Hu T . The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. JACC Basic Transl Sci. 2020; 6(1):1-8. PMC: 7566794. DOI: 10.1016/j.jacbts.2020.10.003. View

Chan K, Lai S, Chu C, Tsui E, Tam C, Wong M . Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6):399-406. View

Sivapalan P, Ulrik C, Lappere T, Eklof J, Shaker S, Bodtger U . Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials. 2020; 21(1):867. PMC: 7573513. DOI: 10.1186/s13063-020-04795-0. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

Reardon S . Cuba's bet on home-grown COVID vaccines is paying off. Nature. 2021; 600(7887):15-16. DOI: 10.1038/d41586-021-03470-x. View

12.

Motamedi H, Mahdizade Ari M, Dashtbin S, Fathollahi M, Hossainpour H, Alvandi A . An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Int Immunopharmacol. 2021; 96:107763. PMC: 8101866. DOI: 10.1016/j.intimp.2021.107763. View

13.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

14.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

15.

Davies B . Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010; 65 Suppl 2:ii5-ii10. PMC: 2835511. DOI: 10.1093/jac/dkq015. View

16.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

17.

Vlachakis D, Papakonstantinou E, Mitsis T, Pierouli K, Diakou I, Chrousos G . Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food Chem Toxicol. 2020; 146:111805. PMC: 7543766. DOI: 10.1016/j.fct.2020.111805. View

18.

Park K, Sun X, Aikins M, Moon J . Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev. 2020; 169:137-151. PMC: 7744276. DOI: 10.1016/j.addr.2020.12.008. View

19.

Oldfield V, Plosker G . Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006; 66(9):1275-99. DOI: 10.2165/00003495-200666090-00012. View

20.

Biswas A, Bhattacharjee U, Chakrabarti A, Tewari D, Banu H, Dutta S . Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?. Crit Rev Microbiol. 2020; 46(2):182-193. PMC: 7157960. DOI: 10.1080/1040841X.2020.1739001. View